Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026)
Immuneering's (IMRX) quarterly Depreciation & Amortization (CF) came in at $81402.0 in Q1 2026, down 4.53% year-on-year from $85261.0 in Q1 2025, and up 7.26% quarter-over-quarter from $75889.0 in Q4 2025.
Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Immuneering's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $81402.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 4.53% year-over-year to $81402.0 in Q1 2026; TTM through Mar 2026 was $320659.0, a 8.61% decrease from a year earlier, with the FY2025 full-year figure at $324517.0, down 8.79% from the prior year.
- Depreciation & Amortization (CF) rose to $81402.0 in Q1 2026 per IMRX's latest filing, from $75889.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $90533.0 in Q2 2024 and bottomed at $47704.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $78841.0 (2025), against an average of $78337.9.
- Across the five-year window, Depreciation & Amortization (CF) jumped 468.33% in 2022 and slipped 11.88% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $76862.0 in 2022, then climbed by 16.77% to $89754.0 in 2023, then decreased by 4.05% to $86116.0 in 2024, then declined by 11.88% to $75889.0 in 2025, then advanced by 7.26% to $81402.0 in 2026.
- Per Business Quant, the three latest IMRX Depreciation & Amortization (CF) figures stand at $81402.0 (Q1 2026), $75889.0 (Q4 2025), and $78841.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - | 81,402.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81,402.00 |
| Mar 31, 2026 | 81,402.00 |
| Dec 31, 2025 | 75,889.00 |
| Dec 31, 2025 | 75,889.00 |
| Sep 30, 2025 | 78,841.00 |
| Sep 30, 2025 | 78,841.00 |
| Jun 30, 2025 | 84,527.00 |
| Jun 30, 2025 | 84,527.00 |
| Mar 31, 2025 | 85,261.00 |
| Mar 31, 2025 | 85,261.00 |
| Dec 31, 2024 | 86,116.00 |
| Dec 31, 2024 | 86,116.00 |
| Sep 30, 2024 | 88,949.00 |
| Sep 30, 2024 | 88,949.00 |
| Jun 30, 2024 | 90,533.00 |
| Jun 30, 2024 | 90,533.00 |
| Mar 31, 2024 | 90,209.00 |
| Mar 31, 2024 | 90,209.00 |
| Dec 31, 2023 | 89,754.00 |
| Dec 31, 2023 | 89,754.00 |